Last Updated: September 17, 2010
The National Cancer Institute is currently recruiting participants to participate in a clinical trial to evaluate IMC-A12 in mesothelioma patients.
Last Updated: June 22, 2010
A clinical trial to study the effects of Everolimus in patients with malignant pleural mesothelioma is currently underway.
WTN News - Madison, WI
June 6, 2008
In an article posted in this column a few weeks ago, it was reported that researchers at Madison-based Quintessence Bioscience were waiting for the results of a Phase IIIb clinical trial from Alfacell Corp., a significant East Coast competitor, on an anti-cancer therapeutic compound,
Onconase. QBI-139, Quintessence's lead drug candidate, is very similar to Onconase but has not yet gone through clinical testing.
7thSpace Interactive
May 1, 2008
An unusual clinical feature of
mesothelioma is the presentation of contralateral mediastinal shift due to pleural mesothelioma tissue, rather than a pleural effusion.
Mesothelioma.com
April 29, 2008
Dr. Paul Sugarbaker, renowned oncologic surgeon specializing in mesothelioma at the Washington Cancer Institute, developed a leading-edge surgical procedure to treat mesothelioma called heated intraoperative intraperitoneal chemotherapy.
Cancer Consultants, ID
April 9, 2008
Researchers have reported that combination resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy is effective for treating malignant
peritoneal mesothelioma.
By Ed Susman
February 6, 2008
Stage 3 pure
epithelial mesothelioma patients who underwent the more extensive treatment of radical decortication/pleurectomy appear to have significantly better results than patients who had less extensive operations.
By Charles Bankhead, Staff Writer, MedPage Today
September 21, 2007
Some
malignant mesothelioma patients may have a
mesothelioma prognosis that's not as grim as once widely believed, said a Nordic collaborative group.
By Peggy Peck, Managing Editor, MedPage Today
June 06, 2007
Confirming results of previous studies, pemetrexed combined with either
cisplatin or
carboplatin demonstrated activity in previously untreated malignant
pleural mesothelioma, said researchers.
By Lise Millay Stevens, Contributing Writer, Health Behavior News Service February 8, 2007
People with mesothelioma � a form of cancer associated with
asbestos exposure � have a higher
survival rate when treated with a combination of two cancer drugs, a large multicenter study finds.
RTT News June 27, 2006
Alfacell Corp. said that according to the research findings published in National Academy of Sciences Journal, the company's anti-cancer drug Onconase might be one of the most effective methods of treatment for mesothelioma and
lung cancer caused by asbestos.
Press Release February 2, 2004
The first and only drug regimen proven to help patients with an
asbestos cancer live longer was approved today by the U.S. Food and Drug Administration.
Reuters October 9, 2002
OSI Pharmaceuticals Inc. is more confident than ever of the potential of its experimental cancer drug Tarceva (erlotinib HCl), even after the failure of a similar drug in a major clinical study this summer, OSI Chairman and CEO Dr. Colin Goddard told investors at the UBS Warburg Global Life Sciences conference here on Wednesday.
No comments:
Post a Comment